Management of older adults with myelodysplastic syndromes (MDS)

被引：14

作者：

Luskin, Marlise R. ^{[1
]}

Abel, Gregory A.

机构：

[1] Dana Farber Canc Inst, 450 Brookline Ave,Dana 2056, Boston, MA 02215 USA

来源：

JOURNAL OF GERIATRIC ONCOLOGY | 2018年 / 9卷 / 04期

关键词：

Myelodysplastic syndromes; Older adults; Frailty; Comorbidity; Allogeneic hematopoietic stem cell transplant; HEMATOPOIETIC-CELL TRANSPLANTATION; QUALITY-OF-LIFE; PROGNOSTIC SCORING SYSTEM; ACUTE MYELOID-LEUKEMIA; RANDOMIZED PHASE-III; TRANSFUSION-DEPENDENT PATIENTS; CONVENTIONAL CARE REGIMENS; COLONY-STIMULATING FACTOR; CLONAL HEMATOPOIESIS; COMORBIDITY INDEX;

D O I：

10.1016/j.jgo.2017.12.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The myelodysplastic syndromes (MDS) are a varied group of hematologic neoplasms that lead to bone marrow failure, and also carry a risk of progression to acute myeloid leukemia. Patients with MDS suffer significant impairments to both their quality of life and survival. Age is the dominant risk factor for the development of MDS, with a median age at diagnosis over 70 years. Consequently, patients with MDS frequently have concurrent comorbidities and/or frailty which may be coincident or related to the disease itself. Disease characteristics, degree of comorbidity, and presence of frailty all impact prognosis. Treatment of MDS focuses on supportive care, with disease-modifying approaches (chemotherapy and allogeneic hematopoietic cell transplantation) reserved for fit patients with high-risk disease. Care of patients with MDS requires understanding the disease in the context of an older population, and tailoring approaches to both disease risk and patient suitability for therapy. (C) 2017 Elsevier Ltd. All rights reserved.

引用

页码：302 / 307

页数：6

共 96 条

[81] How I assess comorbidities before hematopoietic cell transplantation [J].

Sorror, Mohamed L. .

BLOOD, 2013, 121 (15) :2854-2863

[82] Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies [J].

Sorror, Mohamed L. ;

Sandmaier, Brenda M. ;

Storer, Barry E. ;

Franke, Georg N. ;

Laport, Ginna G. ;

Chauncey, Thomas R. ;

Agura, Edward ;

Maziarz, Richard T. ;

Langston, Amelia ;

Hari, Parameswaran ;

Pulsipher, Michael A. ;

Bethge, Wolfgang ;

Sahebi, Firoozeh ;

Bruno, Benedetto ;

Maris, Michael B. ;

Yeager, Andrew ;

Petersen, Finn Bo ;

Vindelov, Lars ;

McSweeney, Peter A. ;

Huebel, Kai ;

Mielcarek, Marco ;

Georges, George E. ;

Niederwieser, Dietger ;

Blume, Karl G. ;

Maloney, David G. ;

Storb, Rainer .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 306 (17) :1874-1883

[83] Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group [J].

Sperr, W. R. ;

Wimazal, F. ;

Kundi, M. ;

Baumgartner, C. ;

Noesslinger, T. ;

Makrai, A. ;

Stauder, R. ;

Krieger, O. ;

Pfeilstoecker, M. ;

Valent, P. .

ANNALS OF ONCOLOGY, 2010, 21 (01) :114-119

[84] Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): Results of a large internet-based survey [J].

Steensma, David P. ;

Heptinstall, Kathleen V. ;

Johnson, Victor M. ;

Novotny, Paul J. ;

Sloan, Jeff A. ;

Camoriano, John K. ;

Niblack, Joyce ;

Bennett, John M. ;

Mesa, Ruben A. .

LEUKEMIA RESEARCH, 2008, 32 (05) :691-698

[85] Myelodysplastic Syndromes: Diagnosis and Treatment [J].

Steensma, David P. .

MAYO CLINIC PROCEEDINGS, 2015, 90 (07) :969-983

[86] When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes? [J].

Steensma, David P. ;

Gattermann, Norbert .

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2013, 26 (04) :431-444

[87] Hematopoietic Growth Factors in Myelodysplastic Syndromes [J].

Steensma, David P. .

SEMINARS IN ONCOLOGY, 2011, 38 (05) :635-647

[88] Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion [J].

Toma, A. ;

Kosmider, O. ;

Chevret, S. ;

Delaunay, J. ;

Stamatoullas, A. ;

Rose, C. ;

Beyne-Rauzy, O. ;

Banos, A. ;

Guerci-Bresler, A. ;

Wickenhauser, S. ;

Caillot, D. ;

Laribi, K. ;

De Renzis, B. ;

Bordessoule, D. ;

Gardin, C. ;

Slama, B. ;

Sanhes, L. ;

Gruson, B. ;

Cony-Makhoul, P. ;

Chouffi, B. ;

Salanoubat, C. ;

Benramdane, R. ;

Legros, L. ;

Wattel, E. ;

Tertian, G. ;

Bouabdallah, K. ;

Guilhot, F. ;

Taksin, A. L. ;

Cheze, S. ;

Maloum, K. ;

Nimuboma, S. ;

Soussain, C. ;

Isnard, F. ;

Gyan, E. ;

Petit, R. ;

Lejeune, J. ;

Sardnal, V. ;

Renneville, A. ;

Preudhomme, C. ;

Fontenay, M. ;

Fenaux, P. ;

Dreyfus, F. .

LEUKEMIA, 2016, 30 (04) :897-905

[89] A Meta-Analysis of the Relationship between Cigarette Smoking and Incidence of Myelodysplastic Syndromes [J].

Tong, Hongyan ;

Hu, Chao ;

Yin, Xiufeng ;

Yu, Mengxia ;

Yang, Jun ;

Jin, Jie .

PLOS ONE, 2013, 8 (06)

[90] Smoking and alcohol and subsequent risk of myelodysplastic syndromes in Japan: the Japan Public Health Centre-based Prospective Study [J].

Ugai, Tomotaka ;

Matsuo, Keitaro ;

Sawada, Norie ;

Iwasaki, Motoki ;

Yamaji, Taiki ;

Shimazu, Taichi ;

Sasazuki, Shizuka ;

Inoue, Manami ;

Kanda, Yoshinobu ;

Tsugane, Shoichiro .

BRITISH JOURNAL OF HAEMATOLOGY, 2017, 178 (05) :747-755

← 1 2 3 4 5 6 7 8 9 10 →